Avicanna Inc. (AVCN.TO)
| Previous Close | 0.2100 |
| Open | 0.2300 |
| Bid | 0.2300 x N/A |
| Ask | 0.2600 x N/A |
| Day's Range | 0.2300 - 0.2400 |
| 52 Week Range | 0.1600 - 1.0800 |
| Volume | |
| Avg. Volume | 56,106 |
| Market Cap | 11.006M |
| Beta (5Y Monthly) | 2.18 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6060 |
| Earnings Date | Nov 12, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.70 |
- GlobeNewswire
Avicanna Sells Stake in Majority-Owned Colombian Subsidiary Sativa Nativa
The company is maintaining operations and its shares in its primary Majority-Owned Subsidiary, Santa Marta Golden Hemp, also based in Santa Marta ColombiaTORONTO, June 24, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products is pleased to announce the sale of its stake in Sativa Nativa S.A.S. (“Sativa Nativa”)
- GlobeNewswire
CEO Presenting on the Emerging Growth Conference on June 22 Register Now
Niche Companies in Biotech, Technology, Rare Earth, Cannabis, Retail Jewelry, and more in attendance.MIAMI, June 21, 2022 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth Companies and Markets announces the Schedule of the 33rd Emerging Growth Conference. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovati
- GlobeNewswire
Avicanna’s Subsidiary Santa Marta Golden Hemp Completes First Commercial Export of Feminized Cannabis Seeds to Lesotho
Avicanna News Aureas Santa Marta This export marks the 16th international market entry for Avicanna and the first export of proprietary genetics into Africa. NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. TORONTO, June 09, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabino
